A Study to Evaluate the Effect of Age, Food and Gender on Tolerability and Pharmacokinetics of GSK2256294 Following a Single Oral Administration in Healthy Fed and Fasted Elderly Subjects. This Study Will Also Evaluate the Biliary Metabolites in Healthy Young Males Following a Single Dose of GSK2256294
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
Price : $35 *
At a glance
- Drugs GSK 2256294 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 05 Jun 2014 Status changed from active, no longer recruiting to completed; as reported by ClinicalTrials.gov record.
- 22 May 2014 Status changed from recruiting to active, no longer recruiting; as reported by ClinicalTrials.gov record.
- 16 Feb 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.